A seasoned pharmaceutical industry executive
with over 40 years at the forefront of innovation, including at
Synthelabo (acquired by Sanofi-Aventis), Dr. Angel aims to propel
MIRA Pharmaceuticals' mission to tackle unmet needs in neurologic
and neuropsychiatric disorders
MIAMI, March 21,
2024 /PRNewswire/ -- MIRA Pharmaceuticals Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), an innovative
pre-clinical-stage pharmaceutical company focused on the
development of novel treatments for neurologic and neuropsychiatric
disorders, proudly announces the appointment of distinguished
pharmaceutical executive Dr. Itzchak
Angel as its new Chief Scientific Advisor.
Dr. Angel brings over 40 years of preclinical, clinical and
regulatory acumen to MIRA. He has significantly contributed to the
research, development and regulatory approval of groundbreaking
medications over his remarkable career. Notably, at Synthelabo
(later acquired by Sanofi-Aventis), Dr. Angel played a pivotal role
in advancing several drugs, including Litoxetine for depression and
Deriglidole for Type-II diabetes, from conception to
Investigational New Drug (IND) applications and clinical trials.
Additionally, his activities contributed to the development and
marketing of Mizollen (mizolastine), Xatral (alfuzosin) and
Ambien (zolpidem).
Beyond his tenure at Synthelabo, Dr. Angel has made significant
advancements in the pharmaceutical industry, including impactful
work at several companies, such as Teva, where he was an external
consultant in strategic drug development and innovation. He has
also founded and served as an officer and director of
several pharma start-ups. He was Vice President for Research
and Development at D-Pharm Biopharmaceuticals, where he
advanced DP-VPA into the human trials for epilepsy and bi-polar
disorders (later licensed to Shire Pharmaceuticals) and the
chelator DP-b99 for stroke (which advanced to phase-III clinical
trials). Dr Angel also served as President and Chief Executive
Officer of stem-cell company Accellta; Vice President for
Research and Development at Proteologics Ltd and at Galmed
Pharmaceuticals (where he advanced Aramchol through an IND to
phase-II clinical trials); Head of Discovery and Research and
Development Concenter Biopharma (where he advanced Zygosid-50
towards clinical trials) and others. His experience extends through
various therapeutic areas and has led to the successful research
and development of several drugs, highlighting his vast expertise
and ability to bring critical treatments through the regulatory
process and ultimately to market.
Dr. Angel's extensive background in drug development, from
preclinical research through clinical trials and market
introduction, positions him well to contribute to MIRA's scientific
endeavors. His leadership is expected to accelerate MIRA's research
and development pipeline, particularly in advancing its flagship
compounds, including the innovative Ketamir-2 for
treatment-resistant depression.
"We are truly honored to have Dr. Angel on our team," stated
Erez Aminov, Chairman & CEO of
MIRA. "His distinguished career across the pharmaceutical industry,
from start-ups to big pharma, his exceptional scientific
skills and his dedication to pharmaceutical innovation will help
propel our promising pre-clinical drug candidates forward. His
expertise will be invaluable as we move our product candidates
towards INDs and through the clinical trial and regulatory
approval process and also as we seek to expand our product
candidate portfolio."
Dr. Angel stated, "I am thrilled to contribute to MIRA's
pioneering efforts in addressing the challenges in neurologic and
neuropsychiatric disorders. I look forward to applying my
experience and insights to help advance MIRA."
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company with two
neuroscience programs targeting a broad range of neurologic
and neuropsychiatric disorders. The Company's novel oral
pharmaceutical marijuana, MIRA-55, is currently under
investigation for treating adult patients suffering from anxiety
and cognitive decline, often associated with early-stage dementia.
MIRA-55, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders.
MIRA also holds the exclusive U.S., Canadian and Mexican rights
for Ketamir-2, a novel, patent pending novel oral
ketamine analog under investigation to potentially deliver
ultra-rapid antidepressant effects, providing hope for individuals
battling treatment-resistant depression, major depressive disorder
with suicidal ideation and post-traumatic stress disorder. The U.S.
Drug Enforcement Administration's scientific review of Ketamir-2
concluded that it would not be considered a controlled substance or
listed chemical under the Controlled Substances Act and its
governing regulations.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of the Company's
management related thereto contains "forward-looking statements,"
which are statements other than historical facts made pursuant to
the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. These statements may be identified by words such
as "Aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans,"
"possible," "potential," "seeks," "will," and variations of these
words or similar expressions that are intended to identify
forward-looking statements. Any statements in this press release
that are not historical facts may be deemed forward-looking. These
forward-looking statements include, without limitation, statements
regarding Ketamir-2's potential in treating certain mental health
conditions. Any forward-looking statements in this press release
are based on the Company's current expectations, estimates and
projections only as of the date of this release and are subject to
a number of risks and uncertainties (many of which are beyond the
Company's control) that could cause actual results (including the
anticipated benefits Dr. Angel's services to the Company) to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These and other risks concerning the
Company's programs and operations are described in additional
detail in its registration statement on Form S-1 and other SEC
filings, which are on file with the SEC
at www.sec.gov and the Company's website at
https://www.mirapharmaceuticals.com/investors/sec-filings. The
Company explicitly disclaims any obligation to update any
forward-looking statements except to the extent required by
law.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-welcomes-dr-itzchak-angel-former-head-of-pharmacology-at-synthelabo-as-chief-scientific-advisor-302096130.html
SOURCE MIRA Pharmaceuticals, Inc.